UCB (NASDAQ:UCBJF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Friday.

According to Zacks, “UCB SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in providing therapy for central nervous system disorders, including epilepsy, diabetic neuropathic pain, sclerosis and Parkinson’s disease. It also provides therapy in the areas of oncology, immunology, inflammation, allergy and respiratory diseases. UCB delivers small and large molecule solutions to specialists for use in the treatment of severe diseases. “

Shares of UCB (NASDAQ:UCBJF) opened at 85.23 on Friday. The firm has a market capitalization of $16.08 billion and a PE ratio of 28.33. UCB has a 52-week low of $58.42 and a 52-week high of $86.75. The company has a 50-day moving average price of $78.90 and a 200 day moving average price of $70.82.

COPYRIGHT VIOLATION WARNING: “UCB (UCBJF) Cut to Hold at Zacks Investment Research” was posted by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/05/20/ucb-ucbjf-cut-to-hold-at-zacks-investment-research.html.

12 Month Chart for NASDAQ:UCBJF

Get a free copy of the Zacks research report on UCB (UCBJF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.